World Pharma News Digest - 12.05.2014
4 views
Skip to first unread message
Ruslan David
May 12, 2014, 4:07:01 AM5/12/14
to worldph...@googlegroups.com
Patient stem cells used to make 'heart disease-on-a-chip'
Harvard scientists have merged stem cell and 'organ-on-a-chip' technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, as it is working proof that a chunk of tissue containing a patient's specific genetic disorder can be replicated in the laboratory.
Read more...
http://www.worldpharmanews.com/research/2771-patient-stem-cells-used-to-make-heart-disease-on-a-chip
New method sneaks drugs into cancer cells before triggering release
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Read more...
http://www.worldpharmanews.com/research/2770-new-method-sneaks-drugs-into-cancer-cells-before-triggering-release
More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day
Today Novartis associates across 55 countries are engaging in local volunteer efforts to support their communities in celebration of the company's annual Community Partnership Day (CPD). This year marks the 18th Community Partnership Day commemorating the 1996 creation of Novartis as a global leader in healthcare. There is strong participation from all Novartis divisions in 2014.
Read more...
http://www.worldpharmanews.com/novartis/2769-more-than-19000-novartis-associates-worldwide-volunteer-for-local-causes-on-community-partnership-day
Pfizer reports first-quarter 2014 results
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC); and the Global Established Pharmaceutical segment (GEP).
Read more...
http://www.worldpharmanews.com/pfizer/2768-pfizer-reports-first-quarter-2014-results
Bone marrow-on-a-chip unveiled
The latest organ-on-a-chip from Harvard's Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could only be studied intact in living animals, Institute researchers report in the May 4, 2014, online issue of Nature Methods. The device, dubbed "bone marrow-on-a-chip," gives scientists a much-needed new tool to test the effects of new drugs and toxic agents on whole bone marrow.
Read more...
http://www.worldpharmanews.com/research/2767-bone-marrow-on-a-chip-unveiled
Remodelling damaged nuclei
Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
Read more...
http://www.worldpharmanews.com/research/2766-remodelling-damaged-nuclei
AstraZeneca Board rejects Pfizer proposal
The Board of AstraZeneca PLC has met and considered the letter from Pfizer Inc. The board said it has "no hesitation in rejecting the proposal", which it believed "inadequate, substantially undervalue" the company.
Read more...
http://www.worldpharmanews.com/astrazeneca/2765-astrazeneca-board-rejects-pfizer-proposal
Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed
Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer's commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.
Read more...
http://www.worldpharmanews.com/pfizer/2764-pfizer-sends-letter-to-rt-hon-david-cameron-mp-regarding-commitments-if-proposed-combination-with-astrazeneca-is-completed
Bayer: Very successful start to 2014
Sales of the Bayer Group advanced by 2.8 percent in the first quarter of 2014 to EUR 10,555 million (Q1 2013: EUR 10,266 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), business expanded by 8.4 percent. EBIT rose by 18.4 percent to EUR 2,096 million (Q1 2013: EUR 1,771 million) after net special items of plus EUR 7 million (Q1 2013: minus EUR 45 million). EBIT before special items increased by 15.0 percent to EUR 2,089 million (Q1 2013: EUR 1,816 million).
Read more...
http://www.worldpharmanews.com/bayer/2763-bayer-very-successful-start-to-2014
Pfizer Confirms prior discussions with AstraZeneca
Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations.
Read more...
http://www.worldpharmanews.com/pfizer/2762-pfizer-confirms-prior-discussions-with-astrazeneca
PharmaNews.eu / Latest News
Atlas shows how genes affect our metabolism
http://www.pharmanews.eu/research-and-development/1440-atlas-shows-how-genes-affect-our-metabolism
CNIO team presents a new strategy to personalise cancer therapies
http://www.pharmanews.eu/research-and-development/1441-cnio-team-presents-a-new-strategy-to-personalise-cancer-therapies
EMA publishes 2013 annual report
http://www.pharmanews.eu/ema/1439-ema-publishes-2013-annual-report
NCI, NCRI and EORTC working group outline risk-assessment approach for biomarker-driven cancer clinical trials
http://www.pharmanews.eu/research-and-development/1438-nci-ncri-and-eortc-working-group-outline-risk-assessment-approach-for-biomarker-driven-cancer-clinical-trials
Patients report high satisfaction with pain treatment
http://www.pharmanews.eu/research-and-development/1437-patients-report-high-satisfaction-with-pain-treatment
SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'
http://www.pharmanews.eu/research-and-development/1436-smartt-e-patch-is-a-winner-at-the-french-worldwide-innovation-challenge
'Dustman' protein helps bin cancer cells
http://www.pharmanews.eu/research-and-development/1435-dustman-protein-helps-bin-cancer-cells
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Harvard scientists have merged stem cell and 'organ-on-a-chip' technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, as it is working proof that a chunk of tissue containing a patient's specific genetic disorder can be replicated in the laboratory.
Read more...
http://www.worldpharmanews.com/research/2771-patient-stem-cells-used-to-make-heart-disease-on-a-chip
New method sneaks drugs into cancer cells before triggering release
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Read more...
http://www.worldpharmanews.com/research/2770-new-method-sneaks-drugs-into-cancer-cells-before-triggering-release
More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day
Today Novartis associates across 55 countries are engaging in local volunteer efforts to support their communities in celebration of the company's annual Community Partnership Day (CPD). This year marks the 18th Community Partnership Day commemorating the 1996 creation of Novartis as a global leader in healthcare. There is strong participation from all Novartis divisions in 2014.
Read more...
http://www.worldpharmanews.com/novartis/2769-more-than-19000-novartis-associates-worldwide-volunteer-for-local-causes-on-community-partnership-day
Pfizer reports first-quarter 2014 results
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC); and the Global Established Pharmaceutical segment (GEP).
Read more...
http://www.worldpharmanews.com/pfizer/2768-pfizer-reports-first-quarter-2014-results
Bone marrow-on-a-chip unveiled
The latest organ-on-a-chip from Harvard's Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could only be studied intact in living animals, Institute researchers report in the May 4, 2014, online issue of Nature Methods. The device, dubbed "bone marrow-on-a-chip," gives scientists a much-needed new tool to test the effects of new drugs and toxic agents on whole bone marrow.
Read more...
http://www.worldpharmanews.com/research/2767-bone-marrow-on-a-chip-unveiled
Remodelling damaged nuclei
Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
Read more...
http://www.worldpharmanews.com/research/2766-remodelling-damaged-nuclei
AstraZeneca Board rejects Pfizer proposal
The Board of AstraZeneca PLC has met and considered the letter from Pfizer Inc. The board said it has "no hesitation in rejecting the proposal", which it believed "inadequate, substantially undervalue" the company.
Read more...
http://www.worldpharmanews.com/astrazeneca/2765-astrazeneca-board-rejects-pfizer-proposal
Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed
Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer's commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.
Read more...
http://www.worldpharmanews.com/pfizer/2764-pfizer-sends-letter-to-rt-hon-david-cameron-mp-regarding-commitments-if-proposed-combination-with-astrazeneca-is-completed
Bayer: Very successful start to 2014
Sales of the Bayer Group advanced by 2.8 percent in the first quarter of 2014 to EUR 10,555 million (Q1 2013: EUR 10,266 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), business expanded by 8.4 percent. EBIT rose by 18.4 percent to EUR 2,096 million (Q1 2013: EUR 1,771 million) after net special items of plus EUR 7 million (Q1 2013: minus EUR 45 million). EBIT before special items increased by 15.0 percent to EUR 2,089 million (Q1 2013: EUR 1,816 million).
Read more...
http://www.worldpharmanews.com/bayer/2763-bayer-very-successful-start-to-2014
Pfizer Confirms prior discussions with AstraZeneca
Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations.
Read more...
http://www.worldpharmanews.com/pfizer/2762-pfizer-confirms-prior-discussions-with-astrazeneca
PharmaNews.eu / Latest News
Atlas shows how genes affect our metabolism
http://www.pharmanews.eu/research-and-development/1440-atlas-shows-how-genes-affect-our-metabolism
CNIO team presents a new strategy to personalise cancer therapies
http://www.pharmanews.eu/research-and-development/1441-cnio-team-presents-a-new-strategy-to-personalise-cancer-therapies
EMA publishes 2013 annual report
http://www.pharmanews.eu/ema/1439-ema-publishes-2013-annual-report
NCI, NCRI and EORTC working group outline risk-assessment approach for biomarker-driven cancer clinical trials
http://www.pharmanews.eu/research-and-development/1438-nci-ncri-and-eortc-working-group-outline-risk-assessment-approach-for-biomarker-driven-cancer-clinical-trials
Patients report high satisfaction with pain treatment
http://www.pharmanews.eu/research-and-development/1437-patients-report-high-satisfaction-with-pain-treatment
SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'
http://www.pharmanews.eu/research-and-development/1436-smartt-e-patch-is-a-winner-at-the-french-worldwide-innovation-challenge
'Dustman' protein helps bin cancer cells
http://www.pharmanews.eu/research-and-development/1435-dustman-protein-helps-bin-cancer-cells
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages